Document is current
Any future updates will be listed below
-
Authors
Legere, Nicholas J.
Hinson, J. Travis
-
Funding
Funding for this research was provided by:
UConn Health
NIH (R01HL165220)
HFSP (981320)
- License Information
-
More Information
Article History
Accepted: 21 August 2024
First Online: 17 September 2024
Declarations
:
: J.T.H. serves on the scientific advisory board of Kate Therapeutics and Tevard Biosciences, has stock or stock options in Kate Therapeutics and Tevard Biosciences, receives consulting fees from Avidity Biosciences and Lexeo Therapeutics, and receives sponsored research funds from Lexeo Therapeutics and Tevard Biosciences. J.T.H. has a patent application submitted that includes CRISPR therapeutics for DCM due to TTN mutations.
: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
